Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC Therapy for Biliary Atresia
NCT07011199Phase 1Not yet recruiting
- Sponsor
- Diponegoro University
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells in biliary atresia (2 arms), sponsored by Diponegoro University. Primary endpoints: Serum Albumin Level at 12 months, Total Bilirubin Level at 12 months and 7 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT07011199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011199.